Nektar Therapeutics

NASDAQ:NKTR

Biotechnology

Healthcare
$34.42 -2.04%

-$1.24 today

Market cap
$987.44M
Beta
1.15
P/E (TTM)
-9.3
EPS (TTM)
-$6.39
52W Low $8.27High $109.00

Volume 0.71M

Average 1.00M

NKTR Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Nektar TherapeuticsNASDAQ: NKTR

Total Equity · Q2 FY2026 · quarter ended Jun 2026

Total equity turns positive

Q2 FY2026 total equity was $903.12M, compared with -$24.21M a year earlier. Over 3 fiscal years it compounded at -37.4% a year.

Context

  • Total equity amounted to 82.5% of total assets at the end of Q2 FY2026, up 70.8 pp from a year earlier.
  • Total equity increased in 1 of the last 3 fiscal years.

What to watch

Whether total equity keeps rising in the next quarterly balance sheet after a +3830.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$903.12M+56.7% QoQ
Last fiscal yearDec 2025
$89.83M+47.9% YoY
Year agoJun 2025
-$24.21M+3830.2% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3830.2%——
1 year+47.9%——
3-year CAGR-37.4%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
89.83M USD
Year-over-year change
+47.9%
4-year CAGR
-39.7%

Total Equity vs competitors

How NKTR compares with its peers on the latest reported figures

  • Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +3830.2% is the highest of 11, against a peer median of -15.2%.
  • Total equity amounts to 82.5% of total assets for NKTR, versus a peer median of 43.5%.
NKTR Competitors
Total Equity for NKTR and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NKTRNektar TherapeuticsJun 2026$903.12M USD+3830.2%-37.4%82.5%
XNCRXencor, Inc.Jun 2026$503.23M USD-18.9%-4.4%69.4%
RCUSArcus Biosciences, Inc.Jun 2026$464M USD-15.5%-1.3%50.2%
IMTXImmatics N.V.Mar 2026€456.28M EUR-15.0%+31.4%83.9%
IMCRImmunocore Holdings plcMar 2026$393.67M USD+4.0%+4.0%36.7%
CRVSCorvus Pharmaceuticals, Inc.Mar 2026$240.68M USD+387.9%+2.9%95.1%
CGENCompugen Ltd.Mar 2026$95.35M USD+67.0%+9.8%65.4%
CHRSCoherus Oncology, Inc.Mar 2026$78.62M USD+142.9%—29.6%
MGNXMacroGenics, Inc.Mar 2026$21.2M USD-73.2%-26.8%9.7%
ANLAdlai Nortye Ltd.Dec 2025-$8.32M USD-132.7%—24.2%
IPHAInnate Pharma S.A.Dec 2025-€21.69M EUR-345.6%—34.6%
Peer median (excluding NKTR) —-15.2%+2.9%43.5%

Competitors are the stored peer set for NKTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents25.22M88.23M35.28M44.25M15.12M
Short-term Investments708.74M416.75M268.34M210.97M230.64M
Net Receivables22.49M8.4M2.25M1.61M1.78M
Inventory15.8M19.2M16.1M00
Other Current Assets00000
Total Current Assets795.58M545.97M330.7M261.29M266.27M
Property, Plant & Equipment (Net)177.54M85.89M36.86M11.82M5M
Goodwill76.5M76.5M000
Intangible Assets00000
Long-term Investments64.83M025.83M26.09M3.49M
Tax Assets00000
Other Non-current Assets2.74M2.25M4.64M4.65M5.65M
Total Non-current Assets321.61M164.63M67.33M42.56M14.14M
Total Assets1.12B710.6M398.03M303.85M280.41M
Account Payables9.75M12.98M9.85M11.56M10.77M
Short-term Debt000020.5M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities15.74M9.58M5.55M5.55M22.27M
Total Current Liabilities85.2M68.2M51.27M61.4M53.54M
Long-term Debt000063.16M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities226.75M162.93M117.26M99.02M8.63M
Total Non-current Liabilities352.48M275.76M215.78M181.71M137.04M
Total Liabilities437.68M343.96M267.05M243.11M190.57M
Common Stock19K19K19K19K2K
Retained Earnings(2.83B)(3.2B)(3.48B)(3.6B)(3.76B)
Accumulated OCI(4.16M)(6.91M)80K61K17K
Other Stockholders Equity00000
Minority Interest00000
Total Equity679.51M366.64M130.99M60.74M89.83M
Total Debt143.18M131.5M117.78M102.56M148.91M
Net Debt117.96M43.27M82.5M58.31M133.79M

Nektar Therapeutics

NASDAQ:NKTR

Intrinsic Alpha fair value

Locked

Current Price

$34.42

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.